Open AccessThe role of PSMD9 in human disease: future clinical and therapeutic implications
Author(s) -
Joanne L. Hopper,
Natasha Begum,
Laura Smith,
Thomas A. Hughes
Publication year - 2015
Publication title -
aims molecular science
Language(s) - English
Resource type - Journals
eISSN - 2372-028X
pISSN - 2372-0301
DOI - 10.3934/molsci.2015.4.476
Subject(s) - regulator , histone acetyltransferase , activator (genetics) , proteasome , acetyltransferase , disease , biology , transcription factor , histone , acetylation , microbiology and biotechnology , genetics , computational biology , medicine , gene
PSMD9 was first characterized as a component of the PA700 proteasomal regulator, and was found to stimulate association of PA700 with the catalytic 20S proteasomal core to form the active 26S proteasome. It was also independently identified under the name “bridge-1” as a transcriptional co-activator that modulates function of the transcription factors PDX-1, E12, and E47, and interacts with the co-activator histone acetyltransferase p300. Here, we discuss the molecular and genetic data linking PSMD9 to a diverse range of conditions including diabetes, cancer, mental health problems, polycystic ovary syndrome and neurodegenerative diseases, and thereby highlight its potential as a therapeutic target in these multiple settings